Fosun Pharma’s Global R&D Head On Original Innovation In China
Original innovation in drug development is vital for Chinese pharmas to grow into international majors within a decade, while originality is not necessarily restricted to the first-in-class category, Xingli Wang, head of Fosun Pharma’s Global R&D, shares his thoughts with Scrip.
![Xingli Wang](https://insights.citeline.com/resizer/v2/UIGZEQX75NGY7C245IZB7A6UKM.jpg?smart=true&auth=6eb20df2a56d989bfab16fd978ccaf06e2061a16b4577f5582d16c79f678d234&width=700&height=394)